Ubs Asset Management Americas Inc Madrigal Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 23,476 shares of MDGL stock, worth $12.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,476
Previous 39,809
41.03%
Holding current value
$12.4 Million
Previous $12 Million
10.63%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding MDGL
# of Institutions
408Shares Held
23.1MCall Options Held
666KPut Options Held
514K-
Baker Bros. Advisors LP New York, NY2.14MShares$1.13 Billion8.0% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$1.06 Billion12.22% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.91MShares$1.01 Billion31.28% of portfolio
-
Janus Henderson Group PLC London, X01.84MShares$975 Million0.41% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.83MShares$970 Million11.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $9.05B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...